These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18847618)

  • 1. Dyslipidemia in youth with diabetes: to treat or not to treat?
    Maahs DM; Wadwa RP; Bishop F; Daniels SR; Rewers M; Klingensmith GJ
    J Pediatr; 2008 Oct; 153(4):458-65. PubMed ID: 18847618
    [No Abstract]   [Full Text] [Related]  

  • 2. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
    Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR
    Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register.
    Eriksson M; Zethelius B; Eeg-Olofsson K; Nilsson PM; Gudbjörnsdottir S; Cederholm J; Eliasson B
    Eur J Cardiovasc Prev Rehabil; 2011 Feb; 18(1):97-105. PubMed ID: 21354969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
    [No Abstract]   [Full Text] [Related]  

  • 6. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Gonna H; Ray KK
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
    J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
    [No Abstract]   [Full Text] [Related]  

  • 8. Simvastatin effectively reduced all triglyceride-rich liporoteins (VLDL and LDL) in type 2 diabetes using VAP analysis.
    Cardiovasc J S Afr; 2006; 17(4):216. PubMed ID: 17001431
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dyslipidemias in type 1 diabetes: a current approach].
    Matheus AS; Cobas RA; Gomes MB
    Arq Bras Endocrinol Metabol; 2008 Mar; 52(2):334-9. PubMed ID: 18438544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
    Armitage J; Collins R
    Heart; 2000 Oct; 84(4):357-60. PubMed ID: 10995396
    [No Abstract]   [Full Text] [Related]  

  • 11. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and lipids - a conundrum.
    Valabhji J; Robinson S
    Diabet Med; 2001 Mar; 18(3):250. PubMed ID: 11318849
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective.
    Parhofer KG
    Atheroscler Suppl; 2015 May; 18():109-11. PubMed ID: 25936313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination lipid therapy in type 2 diabetes.
    Sacks FM; Carey VJ; Fruchart JC
    N Engl J Med; 2010 Aug; 363(7):692-4; author reply 694-5. PubMed ID: 20842772
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-HDL-cholesterol in an adolescent diabetes population.
    Kuryan RE; Jacobson MS; Frank GR
    J Clin Lipidol; 2014; 8(2):194-8. PubMed ID: 24636179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapies for diabetic dyslipidaemia.
    Bell DS; Al Badarin F; O'Keefe JH
    Diabetes Obes Metab; 2011 Apr; 13(4):313-25. PubMed ID: 21205114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.